http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1338594-A4

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb75b0b19820e3833ebdcb31603b242b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-79
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-76
filingDate 2001-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f815a90fc621c153462d04e8f261e4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af0e53b38f4af1abe92c6d69a3729ed8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ee54f48c7ce9b02bd9a1704c95b5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4323fc15d36c065cffdb2faa09edcea1
publicationDate 2004-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1338594-A4
titleOfInvention PGD2 RECEPTOR ANTAGONIST PHARMACEUTICAL COMPOSITIONS
abstract Compounds of the general formula (I) which are metabolically stable and exhibit PGD2 receptor antagonism, wherein Y is a bicyclic ring; R1 is optionally substituted heteroaryl; R2 is hydrogen or the like; R3 is -CH¿2?-CH2-CH2-CH2-CH=CH-COOR?4,- CH¿2-CH2-CH2-CH2-X1-CH2-COOR4, -CH2-CH=CH-CH2-X1-CH2-COOR4, or -CH¿2?-CH2-CH2-CH2-COOR?4; R4¿ is hydrogen or the like; and X1 is -O- or the like.
priorityDate 2000-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0945450-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1016660-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1295872-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155

Total number of triples: 38.